Following a week of positive news regarding the development of a coronavirus vaccine, AstraZeneca announced Monday morning its immunization candidate is 70% effective.
An analysis of large-scale Phase 3 clinical trials of AstraZeneca’s vaccine, called AZD1222, showed the immunization candidate was highly effective in preventing COVID-19, the biopharmaceutical company said in a statement.
AZD1222, developed with the University of Oxford, proved to be 90% effective after one dosing regimen was administered, when given as a half dose followed by a full dose at least one month apart, according to the statement.
The vaccine was 62% effective after another dosing regimen, when given as two full doses at least one month apart, the statement said.
The two numbers average out to the 70% effectiveness, the company noted.
No hospitalizations or severe cases of the disease were reported among participants in the study. There were 131 total coronavirus cases in the analysis, AstraZeneca said.
An independent safety monitoring board determined the analysis of the vaccine candidate met its “primary endpoint,” showing protection from the virus 14 days or more after receiving two doses, according to the company.
“No serious safety events related to the vaccine have been confirmed. AZD1222 was well tolerated across both dosing regimens,” AstraZeneca said.
The company said it will now seek emergency use from the World Health Organization, allowing AZD1222 to be made available in low-income countries. The full analysis of the vaccine’s interim results will also be submitted for publication in a peer-reviewed journal.
“These findings show that we have an effective vaccine that will save many lives. Excitingly, we’ve found that one of our dosing regimens may be around 90% effective, and if this dosing regime is used, more people could be vaccinated with planned vaccine supply,” said Professor Andrew Pollard, chief investigator of the Oxford vaccine trial.
AstraZeneca’s announcement comes only days after Pfizer and BioNTech said they would be asking the federal government for authorization of their coronavirus vaccine.
Both the COVID-19 vaccines developed by Pfizer and BioNTech as well as the Cambridge, Massachusetts-based biotechnology company Moderna have shown to be roughly 95% effective during Phase 3 trials.
More data from AstraZeneca’s vaccine candidate is expected, and additional analysis will be conducted, refining AZD1222′s effectiveness percentage and establishing how long it will protect against the virus, according to the company.
“Today marks an important milestone in our fight against the pandemic. This vaccine’s efficacy and safety confirm that it will be highly effective against COVID-19 and will have an immediate impact on this public health emergency,” Pascal Soriot, CEO of AstraZeneca said.
Related Content:
"severe" - Google News
November 23, 2020 at 07:29PM
https://ift.tt/3foZgkl
AstraZeneca COVID vaccine 70% effective; No hospitalizations or severe cases of disease reported, company says - MassLive.com
"severe" - Google News
https://ift.tt/2OrY17E
Shoes Man Tutorial
Pos News Update
Meme Update
Korean Entertainment News
Japan News Update
Bagikan Berita Ini
0 Response to "AstraZeneca COVID vaccine 70% effective; No hospitalizations or severe cases of disease reported, company says - MassLive.com"
Post a Comment